Learn about our latest activities
FDA investigator completes the fourth inspection from April 11th to April 15th, 2016 at NOVAST covering the following three areas:
1. CGMP
2. PAI (Pre-approval Inspection)
3. First time for PADE (Postmarketing Adverse Drug Experience) inspection.
The fourth US FDA inspection concludes with ZERO 483 observations.